Table 2:
AKI status by treatment arm
| Treatment Arm | ||||
|---|---|---|---|---|
| All | Placebo | Epo | p-values | |
| n | 923 | 454 | 469 | |
| AKI Max Anytime, n (%) | 0.62 | |||
| Stage 0 | 572 (62%) | 274 (60.4%) | 298 (63.5%) | |
| Stage 1 | 183 (19.8%) | 105 (23.1%) | 78 (16.6%) | |
| Stage 2 | 108 (11.7%) | 47 (10.4%) | 61 (13%) | |
| Stage 3 | 60 (6.5%) | 28 (6.2%) | 32 (6.8%) | |
| Severe AKI max anytime, n (%) | 0.20 | |||
| Yes (stage 2 or 3) | 168 (18.2%) | 75 (16.5%) | 93 (19.8%) | |
| No (stage 0 or 1) | 755 (81.8%) | 379 (83.5%) | 376 (80.2%) | |
| AKI Timing (Max SCr) | ||||
| Early (days 3–7), n (%) | 0.76 | |||
| Stage 0 | 811 (87.9%) | 400 (88.1%) | 411 (87.6%) | |
| Stage 1 | 92 (10%) | 45 (9.9%) | 47 (10%) | |
| Stage 2 | 11 (1.2%) | 6 (1.3%) | 5 (1.1%) | |
| Stage 3 | 9 (1%) | 3 (0.7%) | 6 (1.3%) | |
| Middle (days 8–14), n (%) | 0.91 | |||
| Stage 0 | 749 (81.1%) | 368 (81.1%) | 381 (81.2%) | |
| Stage 1 | 90 (9.8%) | 49 (10.8%) | 41 (8.7%) | |
| Stage 2 | 41 (4.4%) | 19 (4.2%) | 22 (4.7%) | |
| Stage 3 | 11 (1.2%) | 2 (0.4%) | 9 (1.9%) | |
| Missing - due to deaths prior to day 8 | 32 (3.5%) | 16 (3.5%) | 16 (3.4%) | |
| Late (days 15 – discharge or 44 weeks), n (%) | 0.56 | |||
| Stage 0 | 626 (67.8%) | 306 (67.4%) | 320 (68.2%) | |
| Stage 1 | 117 (12.7%) | 64 (14.1%) | 53 (11.3%) | |
| Stage 2 | 84 (9.1%) | 37 (8.1%) | 47 (10%) | |
| Stage 3 | 48 (5.2%) | 25 (5.5%) | 23 (4.9%) | |
| Missing - due to deaths prior to day 15 | 48 (5.2%) | 22 (4.8%) | 26 (5.5%) | |
Children who died on days 0, 1, 2 are excluded from this analysis.
Lab data from days 0, 1 are not included in the AKI calculation.
Children may qualify as severe AKI on day 2 via elevated SCr, but not by SCr ratio to baseline.